This webinar will provide a comprehensive overview of cardiovascular disease (CVD) risk among people living with HIV and the underlying factors contributing to this risk. Participants will learn about current risk prediction tools available for assessing CVD risk in people living with HIV, as well as the findings and implications of the REPRIEVE trial. 

---

Learning Objectives
At the end of this webinar, you will be able to:

• Describe the risk of cardiovascular disease in people living with HIV
• Identify the risk factors associated with increased cardiovascular disease risk in people with HIV
• Discuss how current risk prediction tools may be used to discuss cardiovascular disease risk with people living with HIV
• Review the results of the REPRIEVE trial and its influence in current clinical care guidelines for people with HIV

---

Continuing Education Credits
Continuing education credits will be available for this webinar pending accreditation.

---

Faculty
Carlos Malvestutto, MD, MPH is an Associate Professor of Clinical Medicine in the Division of Infectious Diseases at the Ohio State University Wexner Medical Center. Dr. Malvestutto’s research has focused on cardiovascular complications of HIV as well as HIV cure strategies using broadly neutralizing antibodies. He is a member of the Reservoirs, Remission and Cure Transformative Science Group of the AIDS Clinical Trials Group and also serves in the Ending the HIV Epidemic Working Group of the HIV Medical Association.